Ірландія - англійська - HPRA (Health Products Regulatory Authority)

santen oy - dorzolamide; timolol - eye drops, solution - 20+5 milligram(s)/millilitre - beta blocking agents1); timolol, combinations

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - dorzolamide hydrochloride, quantity: 22.3 mg/ml (equivalent: dorzolamide, qty 20 mg/ml) - eye drops, solution - excipient ingredients: benzalkonium chloride; water for injections; sodium hydroxide; hyetellose; sodium citrate dihydrate; mannitol - dorzolamide eye drops are indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

Канада - англійська - Health Canada

alcon canada inc - dorzolamide (dorzolamide hydrochloride) - solution - 2.0% - dorzolamide (dorzolamide hydrochloride) 2.0% - carbonic anhydrase inhibitors

Канада - англійська - Health Canada

bausch & lomb inc - dorzolamide (dorzolamide hydrochloride) - solution - 20mg - dorzolamide (dorzolamide hydrochloride) 20mg - carbonic anhydrase inhibitors

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - dorzolamide hydrochloride - eye drops - 20mg/1ml

США - англійська - NLM (National Library of Medicine)

physicians total care, inc. - dorzolamide hydrochloride (unii: qzo5366ew7) (dorzolamide - unii:9jdx055tw1), timolol maleate (unii: p8y54f701r) (timolol - unii:817w3c6175) - dorzolamide 20 mg in 1 ml - cosopt is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target iop determined after multiple measurements over time). the iop-lowering of cosopt b.i.d. was slightly less than that seen with the concomitant administration of 0.5% timolol b.i.d. and 2.0% dorzolamide t.i.d. (see clinical pharmacology, clinical studies). cosopt is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease (see warnings); (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure (see warnings); (7) cardiogenic shock; or (8) hypersensitivity to any component of this product. please follow these instructions carefully when using cosopt. use cosopt as prescribed by your doctor. - if you use other topically applied ophthalmic medications, they should be administered at lea

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

blumont pharma - dorzolamide hydrochloride - eye drops solution - 20 mg/ml - carbonic anhydrase inhibitors

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

generics (uk) limited - dorzolamide - eye drops solution - 20 mg/ml - carbonic anhydrase inhibitors

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

pharmaswiss ceska republika s.r.o. - dorzolamide hydrochloride; timolol maleate - eye drops, solution - 20mg/ml+5 milligram(s)/millilitre - beta blocking agents1); timolol, combinations

США - англійська - NLM (National Library of Medicine)

akorn - dorzolamide hydrochloride (unii: qzo5366ew7) (dorzolamide - unii:9jdx055tw1), timolol maleate (unii: p8y54f701r) (timolol anhydrous - unii:5jky92s7br) - dorzolamide 20 mg in 1 ml - cosopt® is indicated for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target iop determined after multiple measurements over time). the iop-lowering of cosopt administered twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol administered twice a day and 2% dorzolamide administered three times a day [see clinical studies (14)]. cosopt is contraindicated in patients with bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease [see warnings and precautions (5.1)]. cosopt is contraindicated in patients with sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, and cardiogenic shock [see warnings and precautions (5.2)]. cosopt is contraindicated in patients who are hypersensitive to any component of this product [see warnings and precautions (5.3)]. teratogen